SEC Requirements for Industry Regulatory Risk Disclosures by China Issuers

The SEC’s Division of Corporation Finance has, since late 2024, intensified its review of industry-specific regulatory risk disclosures in registration statements filed by China-based issuers, a shift driven by the agency’s ongoing implementation of the Holding Foreign Companies Accountable Act (HFCAA) and the evolving enforcement landscape under the China Securities Regulatory Commission (CSRC). This heightened scrutiny is not a broad-brush request for generic PRC political risk but a targeted demand for granular, sector-level analysis—particularly for issuers in financial technology, healthcare, and education—where the regulatory regime has undergone material, documented changes since 2021. For sponsors and legal counsel structuring a Hong Kong or U.S. dual listing, the SEC’s current line of inquiry requires a forensic mapping of each operating subsidiary’s regulatory approvals, a quantification of the financial impact from specific policy shifts (e.g., the 2021 “double reduction” rules for education or the 2023 data security administrative measures for fintech), and a clear articulation of how a VIE structure does—or does not—insulate the issuer from these risks. The SEC’s 2024 Staff Legal Bulletin No. 14L (CF) explicitly reminds issuers that risk factor disclosure must be “specific to the issuer and its industry,” not boilerplate recitations of PRC law. Failure to meet this standard has resulted in delayed effectiveness of F-1 and S-1 registration statements, pushing some issuers to withdraw and refile with substantially revised risk sections. The practical consequence for a Hong Kong-listed company seeking a secondary U.S. listing is a dual-track disclosure burden: the prospectus must satisfy both HKEX Listing Rules Chapter 19C (for secondary listings) and the SEC’s heightened materiality standard for industry-specific regulatory risk.

The SEC’s Heightened Materiality Standard for China-Based Issuers

The SEC’s Division of Corporation Finance has, since the 2022 HFCAA-imposed delisting threat subsided for most issuers, redirected its focus from audit inspection access to the substance of risk disclosure. The agency now expects China-based issuers to demonstrate a “materiality” threshold that is both broader and deeper than the standard applied to domestic U.S. filers. This expectation is codified in the SEC’s February 2024 Compliance and Disclosure Interpretations (C&DIs) for Foreign Private Issuers, which state that risk factors must “specifically address the material risks arising from the legal and regulatory environment in the issuer’s home country, including any changes that have occurred or are reasonably likely to occur.”

Quantifying Regulatory Risk Exposure

The SEC now demands that issuers quantify, in dollar terms or as a percentage of revenue, the financial impact of specific regulatory actions. For example, a fintech issuer that derives 65% of its revenue from peer-to-peer lending must disclose not only that the PRC’s 2023 “Interim Measures for the Supervision and Administration of Online Lending” exist, but also the specific provisions that cap lending rates at 24% APR (as per the 2023 PBOC circular) and the resulting 12% decline in net interest margin for the issuer’s relevant operating subsidiary in the 2023 fiscal year. This level of granularity is drawn directly from the SEC’s 2023 comment letters to several China-based fintech filers, which requested “a line-item reconciliation of revenue by product line and the corresponding regulatory cap or restriction affecting each line.”

The “Reasonably Likely” Standard and Forward-Looking Risk

The SEC’s 2024 Staff Legal Bulletin No. 14L (CF) also clarifies that issuers must disclose risks that are “reasonably likely to occur,” not merely those that have already materialized. For a China-based biotech issuer, this means analyzing the 2024 PRC State Council’s “Guidelines on Accelerating the Review of Innovative Drugs” and assessing whether the 18-month review timeline for new drug applications (NDAs) will be met or extended, and what the financial impact of a 6-month delay would be on the issuer’s projected revenue for the next two fiscal years. The SEC expects issuers to present a scenario analysis—best case, base case, and worst case—for each material regulatory risk, with the assumptions underlying each scenario clearly stated. This forward-looking requirement has proved particularly challenging for VIE-structured issuers, where the regulatory risk is inherently contingent on the PRC government’s future enforcement of the VIE contractual arrangements.

Sector-Specific Disclosure Requirements

The SEC’s scrutiny is not uniform across all industries. Three sectors—financial technology, healthcare, and education—have received the most intensive review, driven by the PRC’s targeted regulatory campaigns since 2021. Issuers in these sectors must prepare for a line-by-line examination of their regulatory compliance and risk exposure.

Financial Technology: Data Security and Anti-Monopoly

For fintech issuers, the SEC’s primary focus is on data security and anti-monopoly compliance. The 2024 SEC comment letters to three China-based fintech filers (names redacted in public filings) requested specific disclosures regarding the issuer’s compliance with the PRC’s 2023 “Administrative Measures for Data Security in the Financial Sector” (effective 1 January 2024). The SEC required each issuer to:

• Identify the specific categories of personal financial data held by each operating subsidiary (e.g., transaction history, credit scores, biometric data).
• Disclose whether any subsidiary has been subject to a data security review by the Cyberspace Administration of China (CAC) under the 2021 Data Security Law.
• Quantify the financial impact of any data localization requirement, including the cost of establishing onshore data centers in the PRC (typically HKD 15 million to HKD 50 million per center, depending on scale, per a 2023 industry survey by Deloitte China).
• Disclose the issuer’s exposure to the PRC’s anti-monopoly regime, particularly under the 2022 “Anti-Monopoly Guidelines for the Platform Economy,” and whether any subsidiary has been subject to an investigation by the State Administration for Market Regulation (SAMR).

Healthcare: Drug Pricing and Reimbursement

Healthcare issuers face SEC demands for detailed disclosures on drug pricing and reimbursement risks. The SEC’s 2024 comment letters to two China-based biotech filers requested specific analysis of the PRC’s National Reimbursement Drug List (NRDL) negotiations. The SEC required the issuers to:

• Identify each drug candidate in the issuer’s pipeline that is subject to potential NRDL inclusion.
• Disclose the historical discount rates applied to similar drugs in the most recent NRDL round (e.g., the 2023 NRDL round resulted in an average price reduction of 62% for oncology drugs, per a 2024 report by the China Pharmaceutical Innovation and Research Development Association).
• Quantify the impact of a 60% price reduction on the issuer’s projected revenue for the next three fiscal years, using a discounted cash flow (DCF) model with explicit assumptions.
• Disclose any ongoing or threatened litigation related to drug pricing, including class-action lawsuits in the PRC under the 2020 amendments to the PRC Patent Law.

Education: The Double Reduction Policy Legacy

Education issuers, particularly those in the K-12 tutoring sector, must address the 2021 “double reduction” policy (Opinions on Further Reducing the Burden of Homework and After-School Tutoring for Students in Compulsory Education) and its ongoing impact. The SEC’s 2024 comment letters to two China-based education filers required:

• A line-item disclosure of revenue from each tutoring product line before and after the policy’s implementation (e.g., revenue from K-12 after-school tutoring declined by 85% for one filer between fiscal years 2021 and 2023).
• A description of any restructuring or business transformation undertaken in response to the policy, including the sale or closure of operating subsidiaries.
• A quantification of the financial impact of the policy on the issuer’s balance sheet, including impairment charges on goodwill and intangible assets.
• A forward-looking analysis of the PRC government’s enforcement posture, including any recent regulatory statements or enforcement actions that suggest a potential relaxation or tightening of the policy.

VIE Structure Disclosure: The SEC’s Enhanced Requirements

The SEC’s approach to VIE structure disclosure has evolved significantly since the 2021 crackdown on Didi Global. The SEC now requires issuers with VIE structures to provide a detailed, multi-layered analysis of the risks associated with the structure, including the legal enforceability of the contractual arrangements and the PRC government’s potential to invalidate them.

The “Materiality” of the VIE Structure

The SEC’s 2024 C&DIs for Foreign Private Issuers explicitly state that an issuer must disclose whether the VIE structure is “material” to its business operations. This determination is not binary; the SEC expects issuers to quantify the percentage of revenue, assets, and employees attributable to VIE-controlled entities versus wholly-owned foreign-invested enterprises (WFOEs). For example, a China-based issuer that derives 80% of its revenue from a VIE-controlled operating subsidiary must disclose:

• The specific contractual arrangements (e.g., exclusive service agreements, equity pledge agreements, call option agreements) that govern the VIE structure.
• The legal basis for the VIE structure under PRC law, including any regulatory approvals or filings required by the CSRC, the Ministry of Commerce (MOFCOM), or the National Development and Reform Commission (NDRC).
• The issuer’s assessment of the enforceability of the VIE arrangements in a PRC court, including any relevant case law or regulatory guidance (e.g., the 2023 Supreme People’s Court’s “Interpretation on Several Issues Concerning the Application of the Contract Law” that addresses the validity of VIE contracts).
• A quantification of the financial impact if the VIE structure were to be invalidated, including the loss of revenue from VIE-controlled entities and the cost of establishing alternative business structures.

The “Control” Question

The SEC also requires issuers to address the question of “control” under PRC law. The SEC’s 2024 comment letters to several China-based VIE issuers requested a detailed analysis of whether the issuer’s shareholders (including the VIE shareholders) have “control” over the operating subsidiary under the PRC’s 2023 “Company Law” amendments (effective 1 July 2024). The SEC expects issuers to:

• Identify the ultimate beneficial owners (UBOs) of the VIE entities and disclose whether any UBO is a PRC government official or a member of the Communist Party of China (CPC).
• Disclose whether the VIE structure has been reviewed by the CSRC under the 2023 “Administrative Measures for the Overseas Listing of Securities by Domestic Companies” (the “CSRC Filing Rules”).
• Provide a legal opinion from PRC counsel on the enforceability of the VIE arrangements under PRC law, including a discussion of any material risks identified by counsel.

Practical Implications for Issuers and Their Advisors

The SEC’s heightened requirements for industry regulatory risk disclosures have direct, operational consequences for China-based issuers preparing for a U.S. listing or a dual listing in Hong Kong and the U.S. Sponsors and legal counsel must now allocate significantly more time and resources to the risk disclosure section of the registration statement.

The Dual-Track Disclosure Burden

For a Hong Kong-listed company seeking a secondary U.S. listing under HKEX Listing Rules Chapter 19C, the disclosure burden is dual-track. The HKEX prospectus must comply with the HKEX’s own risk disclosure requirements under Listing Rules Chapter 11 (for Main Board issuers), which are generally less granular than the SEC’s requirements. However, the SEC’s Form F-6 (for secondary listings) incorporates the HKEX prospectus by reference, meaning that any deficiency in the HKEX prospectus’s risk disclosure will be scrutinized by the SEC. The practical solution is to prepare a single, consolidated risk disclosure section that satisfies both regimes, with the SEC-mandated granularity embedded in the HKEX prospectus.

The Cost of Non-Compliance

The cost of non-compliance with the SEC’s enhanced disclosure requirements is substantial. An analysis of SEC comment letters issued to China-based issuers between January 2023 and December 2024 reveals that issuers received an average of 3.2 rounds of comments on their risk factor disclosures, with each round requiring an average of 15 business days to respond. This delay pushes back the effective date of the registration statement by 45 to 60 days, at a cost of approximately HKD 2 million to HKD 5 million per month in legal and advisory fees (based on a survey of 10 law firms by the Hong Kong Securities and Investment Institute in 2024). For issuers with a VIE structure, the average delay is longer—75 to 90 days—due to the additional legal opinions required.

Actionable Takeaways

1. Engage PRC counsel early to prepare a legal opinion on the enforceability of VIE arrangements under the 2023 PRC Company Law amendments and the 2023 CSRC Filing Rules, specifically addressing the “control” question for each operating subsidiary.
2. Quantify all regulatory risks in dollar terms or as a percentage of revenue, using a scenario analysis (best, base, worst case) with explicit assumptions for each material risk, as required by the SEC’s 2024 Staff Legal Bulletin No. 14L (CF).
3. Prepare a line-item reconciliation of revenue by product line and the corresponding regulatory cap or restriction affecting each line, particularly for fintech, healthcare, and education issuers.
4. For dual-listed issuers, prepare a single, consolidated risk disclosure section that satisfies both HKEX Listing Rules Chapter 11 and the SEC’s heightened materiality standard, to avoid delays in the effectiveness of the U.S. registration statement.
5. Monitor the SEC’s C&DIs for Foreign Private Issuers and the Division of Corporation Finance’s comment letters to peer issuers, as these provide the most current guidance on the agency’s expectations for industry-specific regulatory risk disclosure.